We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > chronic lymphocytic leukaemia

News List

FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma europeanpharmaceuticalreview
April 23, 2020
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
US clears Verastem’s Copiktra for blood cancers pharmatimes
September 27, 2018
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small...
US nod for Venclexta/Rituxan combo pharmatimes
July 10, 2018
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen's Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).